105 Panel: Addressing the Opioid Crisis: Pain Management, Addiction Treatment, and Recovery in the Context of APMs
Welcome

Bill Hazel
Former Secretary, Health and Human Resources,
Commonwealth of Virginia
Panel Speakers

Mary Applegate
Medical Director, Ohio Department of Medicaid

Andrey Ostrovsky
CEO, Concerted Care Group

Martin Rosenzweig
Senior Behavioral Medical Director, Optum

J. Alice Thompson
Social Science Researcher, Center for Medicare and Medicaid Innovation
Three Ways APMs Can Help Combat the Opioid Epidemic
Welcome

Mary S. Applegate, MD, FAAP, FACP

Medicaid Medical Director
Ohio Department of Medicaid
Ohio’s goal: 80-90% in APMs within 5 years

Progress to date

<table>
<thead>
<tr>
<th>Comprehensive Primary Care (CPCs)</th>
<th>Episodes</th>
<th>Behavioral Health Care Coord. (BHCCs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1M+ patients</td>
<td>1M+ patients</td>
<td><em>In design: delegating care coordination to qualified BH entities</em></td>
</tr>
<tr>
<td>145 CPC practices</td>
<td>43 episodes</td>
<td></td>
</tr>
<tr>
<td>~10,000 primary care practitioners</td>
<td>13,000+ providers (PAPs)</td>
<td></td>
</tr>
</tbody>
</table>
3 ways APMs can address the opioid epidemic

I Metrics: include opioids-related quality metrics linked to payment

II Reporting: increase transparency and provide actionable insights

III Predictive Analytics: for earlier identification and intervention
Safer opioid prescriptions tied to incentives

Variation in new opioid prescription (fill) rate

<table>
<thead>
<tr>
<th>Condition</th>
<th>Min</th>
<th>Median</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hysterectomy</td>
<td>50</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Headache</td>
<td>9</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Low back pain</td>
<td>25</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>15</td>
<td></td>
<td>100</td>
</tr>
</tbody>
</table>

Source: Ohio claims data. Episodes ending in 2014
Include OUD care metrics in APMs

Examples of OUD care metrics under consideration

- % members with OUD not receiving any treatment
- Opioid-related ED / IP visits per 1,000 member months
- % patients receiving > 80mg MED
- % members with # urine drug screens per month while receiving MAT
- % members not screened for Hepatitis B or C
Hospital-level change through APMs:
Care Innovation and Community Improvement Program (CICIP)

- Additional upside payment to hospitals through managed care plans
- Conditional to specific opioid-related quality metrics
- To align quality improvement strategies

Examples of CICIP measures:

- % patients on opioids AND benzodiazepine
- % patients receiving > 80mg MED
- Follow-up after inpatient mental health stay
- Improvement of maternity measures
- ED utilization reduction
Reporting for Insight and Action

Patient journey dashboard

<table>
<thead>
<tr>
<th>Patient with CONSISTENT adherence</th>
<th>Medical</th>
<th>MAT</th>
<th>Opioid</th>
<th>Drug Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient with LOW adherence</th>
<th>Medical</th>
<th>MAT</th>
<th>Opioid</th>
<th>Psychosocial</th>
<th>Drug Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Care gap
## Reporting for Insight and Action

Referral reports may drive improved quality and costs of care.

### ASTHMA EXACERBATION – REFERRAL REPORT

<table>
<thead>
<tr>
<th>Provider (PAP)</th>
<th>Risk-adj. cost</th>
<th>Meets quality standards</th>
<th># of episodes from your patients</th>
<th>% of your episodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider 1</td>
<td>$</td>
<td>✓</td>
<td>18</td>
<td>15%</td>
</tr>
<tr>
<td>Provider 2</td>
<td>$$</td>
<td>✗</td>
<td>15</td>
<td>13%</td>
</tr>
<tr>
<td>Provider 3</td>
<td>$$ $$ $$ $$</td>
<td>✓</td>
<td>11</td>
<td>9%</td>
</tr>
</tbody>
</table>
Predictive modeling: population health insights

OUD risk in your panel

% of members

Level 1 - Little or no risk for OUD
Level 2 - Moderate risk for OUD
Level 3 - High risk for OUD
Level 4 - Diagnosed with OUD

Q1 2018: 37% Level 1, 25% Level 2, 20% Level 3, 18% Level 4
Q1 2019: 39% Level 1, 27% Level 2, 18% Level 3, 16% Level 4
### Predictive modeling: population health insights

#### Risk factor prevalence in OUD-diagnosed population % members

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>High-risk factors</th>
<th>Moderate-risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4+ prescribers for opioids</td>
<td>22%</td>
<td>Previous ED visit for OUD</td>
</tr>
<tr>
<td>4+ pharmacies for opioids</td>
<td>13%</td>
<td>Previous overdose</td>
</tr>
<tr>
<td>Crisis visits</td>
<td>7%</td>
<td>Non-OUD SUD diagnosis</td>
</tr>
<tr>
<td>Homelessness</td>
<td>2%</td>
<td>Concurrent benzo. prescription</td>
</tr>
</tbody>
</table>

#### SDoH risk factors

- Detox visits 7%
- Previous overdose 34%
- Non-OUD SUD diagnosis 30%
- Concurrent benzo. prescription 8%
- Previous ED visit for OUD 49%
Additional Considerations

**Prevention**
- *School-based health* incentives for CPCs
- Further leverage & evolve *predictive modelling*
- Link opioids-specific metrics to payment in more episodes, CPC, aligning with PDMP
- Opportunities with 100% *e-prescribing*
- Expand models to include pain management avoid unintended consequences for chronic pain patients

**Treatment**
- Link payment to retention in care (referrals, pain management)
- Further leverage CPC with long-acting MATs
- HCC program to refer to highest quality OUD treatment providers
Implementing Evidence-based Addiction Treatment in the Context of Upstream Barriers to Health

Andrey Ostrovsky MD | CEO | Concerted Care Group | @andreyostrovsky
Welcome

Andrey Ostrovsky
CEO, Concerted Care Group
Faculty Disclosure

Andrey Ostrovsky, MD

Source: socialinnovationventures.co
Catharsis at the front line

• **Vision:** Eliminate addiction in all American communities

• **Mission:** Empower every individual with the ability to improve the quality of their life through comprehensive, integrated, and evidence-based addiction treatment.

• **True North Goals:**
  • Improve clinical outcomes
  • Become financially sustainable
  • Increase joy at work
4 pillars of MAT

• Medication (methadone, buprenorphine, or naltrexone)
• Primary care
• Addictions counseling and mental health therapy
• Social supports

Source: https://www.samhsa.gov/medication-assisted-treatment/treatment
OTP vs OBOT

• Opioid Treatment Program (OTP)
  • SAMHSA-licensed via CARF or Joint Commission to administer methadone for opioid use disorder
  • Can administer methadone, buprenorphine and naltrexone as well
  • Sometimes referred to as “methadone clinic”

• OBOT (Office-based Outpatient Treatment)
  • Individual providers need to have a DATA 2000 waiver
  • Can administer buprenorphine and naltrexone, but not methadone

Source: https://www.samhsa.gov/medication-assisted-treatment/treatment
Dispelling Myths about MAT

**MAT JUST TRADES ONE ADDICTION FOR ANOTHER:** MAT bridges the biological and behavioral components of addiction. Research indicates that a combination of medication and behavioral therapies can successfully treat SUDs and help sustain recovery. (10)

**MAT IS ONLY FOR THE SHORT TERM:** Research shows that patients on MAT for at least 1-2 years have the greatest rates of long-term success. There is currently no evidence to support benefits from stopping MAT. (11)

**MY PATIENT’S CONDITION IS NOT SEVERE ENOUGH TO REQUIRE MAT:** MAT utilizes a multitude of different medication options (agonists, partial agonists and antagonists) that can be tailored to fit the unique needs of the patient. (2)

Source: TheNationalCouncil.org
Dispelling Myths about MAT

**MAT INCREASES THE RISK FOR OVERDOSE IN PATIENTS:** MAT helps to prevent overdoses from occurring. Even a single use of opioids after detoxification can result in a life-threatening or fatal overdose. Following detoxification, tolerance to the euphoria brought on by opioid use remains higher than tolerance to respiratory depression. (14)

**PROVIDING MAT WILL ONLY DISRUPT AND HINDER A PATIENT’S RECOVERY PROCESS:** MAT has been shown to assist patients in recovery by improving quality of life, level of functioning and the ability to handle stress. Above all, MAT helps reduce mortality while patients begin recovery.

**THERE ISN’T ANY PROOF THAT MAT IS BETTER THAN ABSTINENCE:** MAT is evidence-based and is the recommended course of treatment for opioid addiction. American Academy of Addiction Psychiatry, American Medical Association, The National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, National Institute on Alcohol Abuse and Alcoholism, Centers for Disease Control and

Source: TheNationalCouncil.org
Dispelling Myths about MAT

MOST INSURANCE PLANS DON’T COVER MAT: As of May 2013, 31 state Medicaid FFS programs covered methadone maintenance treatment provided in outpatient programs (4). State Medicaid agencies vary as to whether buprenorphine is listed on the Preferred Drug List (PDL), and whether prior authorization is required (a distinction often made based on the specific buprenorphine medication type). Extended-release naltrexone is listed on the Medicaid PDL in over 60 percent of states. (5)

Source: TheNationalCouncil.org
Role of Non-Healthcare Determinants

Source: Schroeder. NEJM. 2007. Adapted from McGinnis et al.
Role of Social Determinants of Health

Role of Social Determinants of Health

Stigma

Economic and social opportunities and resources

Living and working conditions in homes and communities

Medical care

Personal behavior

Health

Policies to promote economic development, reduce poverty, and reduce racial segregation
Policies to promote child and youth development and education, infancy through college
Policies to promote healthier homes, neighborhoods, schools, and workplaces

Role of Social Determinants of Health
Pathways to OUD

• Pathway 1: Inadequately controlled chronic physical pain leads to misuse (17%)
• Pathway 2: Some individuals are vulnerable to opioid dependence even after brief opioid exposure (12%)
• Pathway 3: Prior substance use problems and introduction of prescribed opioids (15%)
• Pathway 4: Relief from emotional distress reinforces misuse or abuse (21%)
• Pathway 5: Recreational initiation or non-medically supervised use of opioids (40%)

"Gas and go" vs Comprehensive care vs "Abstinence"


Fig. 1. Percent urine tests positive for opiates by assessment month and treatment condition. (♦, 21-day methadone detoxification; ▲, 6-month methadone maintenance with minimal counseling; △, 6-month methadone maintenance with standard counseling) Although the standard errors of some of the proportions may overlap [SEP = p(1 − p)/n], the combined difference was statistically significant. Opiate positive urine tests months 1–6: Minimal MM vs. Detox p = .0302. Opiate positive urine tests months 1–8.5: Minimal MM vs. Detox p = .0149.
“Gas and go” vs Comprehensive care vs “Abstinence”

“Gas and go” vs Comprehensive care vs “Abstinence”

4 out of 20 people died in the placebo arm versus none in the buprenorphine group (p = 0.015)

Care needs to be individualized

Opinion

Addiction Doesn’t Always Last a Lifetime

In fact, most people recover, often on their own. Here are some of their stories.

Source: Szalavitz M. NYT. Aug 2018.
How to manage patients not adhering to treatment

How to manage patients not adhering to treatment

<table>
<thead>
<tr>
<th>Phases of Recovery</th>
<th>Criteria</th>
<th>Treatment</th>
</tr>
</thead>
</table>
| **Orange Phase: Induction Phase / or TOP** | First 4 weeks Assessment / getting to know each other | • 1 counseling session per week  
• 1 group per week – to include Orientation group & overdose prevention group  
• 2 MD/NP meetings  
• Weekly urinalysis |
| **Yellow Phase: Intensive Phase** | Current struggle with maintaining abstinence | • 1 counseling session per week  
• 2 groups per week  
• 2 MD/NP meetings per month  
• Weekly urinalysis |
| **Green Phase: Moderate Phase** | Some use may continue now & then. Earning some take homes or working towards earning take homes, moderately engaged in treatment. | • 2 counseling sessions per month  
• 1 group per week  
• 1 MD/NP meetings per month  
• Monthly urinalysis |
| **Blue Phase: Maintenance Phase** | Abstinence from all substances maintained. Receiving take homes. | • 1 60 minute counseling session per month  
• 1 MD/NP visit every 3 months  
• Monthly urinalysis |

**Red Phase: Harm Reduction**

- Non-adherence to treatment plan
  - Non-preferential dosing times
  - Weekly urinalysis
How to manage patients not adhering to treatment

Figure 3.
Time to relapse during 9 months of follow-up; vocational rehabilitation (VR) only versus VR plus contingency management (CM). Note: Sobriety incentives were available weeks 1–16 only.

Source: Drebing CE et al. Adding contingency management intervention to vocational rehabilitation: Outcomes for dually diagnosed veterans. JRRD. 2007. 44(6)
CMS Innovation Center Opioid Strategy and Current Efforts

J. Alice Thompson
Center for Medicare & Medicaid Innovation (CMMI)
Centers for Medicare & Medicaid Services (CMS)
Welcome

J. Alice Thompson
Social Science Researcher, Center for Medicare and Medicaid Innovation
The CMS Innovation Center Statute

“The purpose of the [Center] is to test innovative payment and service delivery models to reduce program expenditures...while preserving or enhancing the quality of care furnished to individuals under such titles.”

Three scenarios for success from Statute:
1. Quality improves; cost neutral
2. Quality neutral; cost reduced
3. Quality improves; cost reduced (best case)

If a model meets one of these three criteria and other statutory prerequisites, the statute allows the Secretary to expand the duration and scope of a model through rulemaking.
CMS Value-Based Payment Framework

Category 1
Fee for Service – No Link to Quality & Value

Category 2
Fee for Service – Link to Quality & Value

Category 3
APMs Built on Fee-for-Service Architecture

Category 4
Population-Based Payment

CMS Roadmap to Address the Opioid Crisis

PREVENTION
Significant progress has been made in identifying overprescribing patterns
1. Identify and stop overprescribing of opioids
2. Enhance diagnosis of OUD to get people the support they need earlier
3. Promote effective, non-opioid pain treatments

TREATMENT
Medicare, Medicaid, and private health plans provide some coverage for pain and opioid use disorder treatments
1. Ensure access to treatment across CMS programs and geography
2. Give patients choices for a broader range of treatments
3. Support innovation through new models and best practices

DATA
Data provides insight into doctor, pharmacy, and patient use of prescription opioids and effectiveness of treatment
1. Understand opioid use patterns across populations
2. Promote sharing of actionable data across continuum of care
3. Monitor trends to assess impact of prevention and treatment solutions

The Integrated Care for Kids (InCK) Model is a child-centered local service delivery and state payment model aimed at reducing expenditures and improving the quality of care for children covered by Medicaid and CHIP, especially those with or at-risk for developing significant health needs.

Up to 8 cooperative agreement awards anticipated Summer 2019

Goals:

1. Improving performance on priority measures of child health
2. Reducing avoidable inpatient stays and out-of-home placements
3. Creation of sustainable Alternative Payment Models (APMs)
Visit the LAN Website for our Resources

https://hcp-lan.org/
Exit Survey

We want to know what you think!

Please take a moment to complete the exit survey so we can continue to improve and enrich the LAN. Use the link in *Guidebook* for this session to provide us your feedback.
Contact Us
We want to hear from you!

www.hcp-lan.org

@Payment_Network

PaymentNetwork@mitre.org

Search: Health Care Payment Learning and Action Network
Thank You!

Partnering for the Future

LAN SUMMIT
Health Care Payment Learning & Action Network

Thank You!